US mRNA specialist Moderna has announced that the UK Court of Appeal has upheld the validity of its EP'949 patent.

BioNTech (NASDAQ:BNTX) is scheduled to announce Q2 earnings results on Monday, August 4th, before market open. The consensus EPS Estimate is -$1.65 (+50.9% Y/Y) and the consensus Revenue Estimate is ...

Analysts estimate that BioNTech will report an earnings per share (EPS) of $-1.31. The market awaits BioNTech's announcement, ...

America’s Car-Mart (CRMT) received an expected notice from the Listing Qualifications Staff of The Nasdaq Stock Market indicating that, as a ...

Moderna beat Q2 earnings and revenue estimates, narrowed its annual forecast, won a key patent case, and plans to cut 10% of ...

Pfizer (PFE) and BioNTech (BNTX) lose bid to appeal a High Court ruling that issued Moderna (MRNA) a COVID-19 vaccine patent ...

CAMBRIDGE, MA / ACCESS Newswire / August 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the UK Court of Appeal has upheld the validity of Moderna's EP'949 patent. This decision affirms the ...

Market Catalysts host Julie Hyman tracks today's top moving stocks and biggest market stories in this Market Minute. Arm ...

Bristol-Myers Squibb (NYSE:BMY) posted second-quarter earnings that surpassed analyst expectations, largely thanks to robust ...

Bristol-Myers Squibb reported second-quarter earnings that exceeded analyst expectations, driven by strong performance across ...

Pfizer should have different top-selling drugs in 2030 with a heavier focus on oncology. The drugmaker should be more ...

Tempus AI's growth is fueled by data services and acquisitions, despite financial risks. Key Q2 results may shape its path to ...